Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines

Background: Lapatinib is a dual epidermal growth factor receptor (EGFR) and HER2 inhibitor. Overexpression of these receptors is frequently observed in head and neck squamous cell carcinoma (HNSCC). As growing proportion of HNSCC is characterized by human papillomavirus (HPV) infection, we aimed at evaluating the efficacy of lapatinib as function of HPV status in HNSCC cell lines.

Methods: Two HPV-positive and two HPV-negative HNSCC cell lines were used. Proliferation, cell cycle, and Annexin V assays were performed to test their sensitivity to lapatinib. Combination of lapatinib and ionizing radiation was evaluated with clonogenic survival assays. Akt, EGFR and HER2, and E6/E7 expression and activation were analyzed by immunoblotting and quantitative reverse transcription polymerase chain reaction.

Results: Lapatinib reduced E6 and E7 expression and Akt phosphorylation, inhibited cell proliferation and induced cell death in HPV-positive cell lines. An additive effect of lapatinib with radiation was observed in these cells. Lapatinib had no effect on HPV-negative cells.

Conclusion: Lapatinib efficacy restricted to the HPV-positive cells suggests that HPV status could be a potential marker for enhanced response to lapatinib in HNSCC.

Keywords: HPV, lapatinib, ionizing radiation, EGFR, HER2, tyrosine kinase inhibitor

Introduction

Head and neck squamous cell carcinoma (HNSCC) is a challenge in oncology. Despite the improvement of therapies, 40%–50% of patients treated for HNSCC experience recurrence. Treatment is generally limited to surgery, platinum-based chemotherapy, and radiotherapy (RT). However, since toxicity and insufficient efficacy are frequent and limiting, targeted molecular therapy has been investigated in the last 20 years. The spectrum of known risk factors is growing. The human papillomavirus (HPV) infection has emerged as an important one, accounting for an increasing proportion of HNSCC. HPV-positive tumors differ from HPV-negative tumors in many aspects, including histological appearance and differentiation. HPV-positive tumors are associated with better prognosis, but the reasons for this remain unclear. Some studies suggested that increased sensitivity to radiation in HPV-positive tumors could account for improved prognosis in these patients. The identification of new, more effective treatments for such cancers, specifically administered depending on the HPV status, could be very useful in the clinical therapy.

The epidermal growth factor receptor (EGFR) family contains four tyrosine kinase transmembrane receptors: EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). These receptors transmit signals through intracellular pathways that regulate...
proliferation, survival, cell cycle progression, and angiogenesis. In HNSCC, EGFR and HER2 are frequently overexpressed, and these alterations correlate with the worse overall survival. EGFR family members thus represent prominent and attractive molecular targets for therapeutic intervention in HNSCC. The relationship between EGFR expression and HPV status is also important. HPV-positive tumors with low EGFR expression are associated with positive response, whereas HPV-positive tumors with high EGFR expression are associated with poor outcome. These results further support the interest in blocking the EGFR pathway.

Cetuximab, a monoclonal antibody EGFR inhibitor, has shown promising therapeutic effects in HNSCC. Other tyrosine kinase inhibitors (TKIs), used in monotherapy, such as gefitinib or erlotinib, have been developed and tested. More recently, strategies targeting both EGFR and HER2 have been proposed; these combination strategies are expected to be more effective than mono-inhibitors. Nevertheless, published studies with anti-EGFR family members, such as cetuximab, gefitinib, erlotinib, lapatinib, and panitumumab, in cervical carcinoma and HNSCC (summarized in Table 1) show discordant results, suggesting that further studies are required to optimize the efficacy of these molecules.

Lapatinib is a reversible dual EGFR and HER2 inhibitor. Lapatinib binds to the ATP-binding pocket of the EGFR and HER2 tyrosine kinase receptors and is approved for use in nonmetastatic, recurrent, and metastatic breast cancer. Lapatinib is a competitive inhibitor of EGFR and HER2 and competes with ATP for the ATP-binding site of the kinases. It is believed to be effective against tumors with high expression of both EGFR and HER2. The drug is well tolerated and has shown evidence of clinical activity in various types of cancer, including breast cancer and HNSCC.

### Table 1 EGFR family inhibitors in cervical carcinoma and HNSCC

| Drug       | Organ      | Authors                  | Phase | Treatment          | Stage of disease | Results                                                                 |
|------------|------------|--------------------------|-------|--------------------|------------------|-------------------------------------------------------------------------|
| Cetuximab  | Cervix     | Santin et al²⁰           | II    | Drug alone         | Persistent or recurrent | Well tolerated, limited to patients with squamous cell histology |
|            |            | Farley et al²⁹           | II    | Cisplatin          | Advanced, persistent, recurrent | No indication of additional benefit beyond cisplatin therapy |
|            |            | Kurtz et al⁴⁰            | II    | Cisplatin + topotecan | Advanced | High rate of serious adverse fatal events |
|            | HNSCC      | Bourhis et al⁴¹          | I/II  | Cisplatin/ carboplatin + 5FU | Recurrent or metastatic | Well tolerated, active in recurrent/metastatic HNSCC |
|            |            | Merlano et al⁴²          | II    | Cisplatin + 5FU + RT | Stage III–IV M0 | Very high proportion of CR feasible |
|            |            | Baselga et al⁴³          | II    | Platin             | Recurrent or metastatic | Active and well tolerated |
|            |            | Bonner et al⁴⁴           | III   | Cisplatin + RT    | Locoregionally advanced | Improves locoregional control and reduces mortality |
|            |            | Burtness et al⁴⁴         | III   | Cisplatin          | Recurrent, metastatic | Improves response rate, progression-free and overall survival not significantly improved |
| Panitunumab| HNSCC      | Vermorken et al²⁵        | III   | Platin + SFU       | Recurrent, metastatic | Improvement in OS |
|            |            | Vermorken et al²⁹        | III   | Platin + RT        | Non-treated stage III–IV | No improvement |
| Gefitinib  | Cervix     | Goncalves et al⁴⁶        | II    | Drug alone         | Locally advanced metastatic | 20% of stable disease |
|            | HNSCC      | Chen et al⁴⁷             | I     | RT ± cisplatin     | Locally advanced | Well tolerated with concomitant boost RT or concurrent CRT |
|            |            | Perez et al⁴⁸            | II    | Drug alone         | Recurrent, metastatic | Active and feasible |
|            |            | Gregoire et al⁴⁹         | III   | Cisplatin + RT    | Untreated, unresected, stage III/IV nonmetastatic | Well tolerated, no improvement in efficacy |
| Erlotinib  | Cervix     | Cohen et al³²            | III   | Carbo/paclitaxel + RT | Locally advanced | OS and CR improvement |
|            |            | Schilder et al³²         | II    | Cisplatin + RT    | IIB and IIIB stages | Feasible |
|            | HNSCC      | Rusthoven et al³⁷        | I     | Drug alone         | Recurrent | Inactive |
|            |            | Arias de la Vega et al³⁴| I     | Cisplatin + RT    | All stages | Feasible |
|            |            | Soulieres et al³⁵        | II    | Drug alone         | Locally advanced | Safe combination |
|            |            | Herchenhorn et al³⁶      | I/II  | Cisplatin/Rt      | Recurrent or metastatic | Stabilized diseases |
|            | HNSCC      | Harrington et al³⁷       | II    | Cisplatin/Rt      | Locally advanced | Feasible and well tolerated |
|            |            | Del Campo et al³⁷        | II    | Drug alone         | Before CRT | Positive clinical activity, reduction of cell proliferation index |

**Abbreviations:** HNSCC, head and neck squamous cell carcinoma; RT, radiotherapy; OS, overall survival; PFS, progression-free survival; HPV, human papillomavirus; CRT, chemoradiotherapy; 5FU, 5-fluorouracil; CR, complete response.
HER2 protein kinase domain, preventing self-phosphorylation of the receptors and signaling activation.20 The drug is administered orally and has already been used with success in some pathologies, such as locally advanced or metastatic breast cancer.21 Several trials have shown that lapatinib can be combined with RT both safely and effectively.22 Phase III clinical studies assessing the relationship between HPV status, treatment with TKIs, and ionizing radiation have not yet been completed in HNSCC, but the results obtained in cervical cancers (about 90% are HPV positive) are controversial, demonstrating only little benefits of using TKIs or an antibody combined with radiation (Table 1). In vitro, other TKIs (erlotinib) have shown growth inhibition and prevented immortalization of HPV-transfected cell lines.23 An HNSCC tumor xenograft showed that erlotinib combined with RT dramatically inhibited tumor growth.24 These data may suggest a benefit of using the combination of ionizing radiation and lapatinib in HNSCC cell lines. The purpose of this study was to evaluate the efficacy of lapatinib alone or in combination with ionizing radiation as function of HPV status in four HNSCC cell lines.

Materials and methods

Drug

Lapatinib was provided as powder by GlaxoSmithKline (GSK; London, UK). A 10−3 M concentrated stock solution was obtained after solubilization in dimethylsulfoxide (DMSO).

Cell culture

Four cell lines were used, including two HPV-positive and two HPV-negative cell lines. Cell lines were maintained at 37°C with 5% carbon dioxide. SCC-9, derived from a tongue epidermoid carcinoma, was obtained from American Type Culture Collection (ATCC; ATCC Number: CRL-1629) and certified as negative for HPV. SCC-15 is also derived from a tongue epidermoid carcinoma, were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ Number: ACC 669; Heidelberg, Germany) and are HPV16 positive. SCC-154 cells were maintained in Minimal Essential Medium supplemented with 10% FBS, 1% P/S, and 1% nonessential amino acids.

Reverse transcription PCR

Quantitative polymerase chain reaction (PCR) analysis was performed to compare the expression of the E6 and E7 oncoproteins between each cell line. RNA extraction was performed using Qiagen RNeasy kit, and the samples were treated with DNase-I (Qiagen). One microgram of total RNA was retrotranscribed using the Bio-Rad™ I-Script kit. Quantitative PCR was performed using the primers listed in Table S1, used at 400 nM concentration. The transcript levels of E6 and E7 were normalized to those of β-2 microglobulin to account for variability in the amount of cDNA in each sample. SYBR Green Mix (Applied Biosystems) was used with the GeneAmp 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using a two-step amplification protocol (Table S1). The relative transcript expression levels were calculated using the ΔΔCT method, using vehicle-treated cells as calibrator.

Proliferation assays

Cells (2,000 cells/well for SCC-9 and SCC-47 and 4,000 cells/well for SCC-15 and SCC-154) were seeded in 96-well plates in a final culture volume of 100 µL for 16 hours before the addition of 100 µL of increasing concentrations of lapatinib (from 1.5 nM to 10 µM). The plates were incubated for 48 hours after the drug was added. The viable cell number was determined using a 10% concentration of UptiBlue reagent (Interchim, France). The analyses were performed by fluorimetry and normalized to a non-treated control. IC50 values represent the concentration which reduces by 50% the number of viable cells.

Cell cycle analysis and Annexin V staining

Cells were treated with vehicle, lapatinib, or staurosporine for 24 hours after plating. One day later, cells were harvested, washed with ice-cold phosphate-buffered saline, and fixed with 70% ethanol. DNA content was labeled with propidium iodide (PI) in the presence of RNase (phosphate-buffered saline buffer supplemented with PI 20 µg/mL, RNase 100 µg/mL, and ethylenediaminetetraacetic acid 20 mM, pH 8). Cells were then incubated for 1 hour at 37°C. FACSCalibur (Becton Dickinson) was used to perform the flow cytometry assay.
At the same time point, dead and apoptotic cells were detected using a fluorescein isothiocyanate-labeled Annexin V kit (Myltenyi Biotec) following manufacturer’s instructions.

Clonogenic survival assays
To determine the sensitivity of the HNSCC cell lines to radiation, we performed clonogenic survival assays. Cells were plated at several low densities depending on the dose rate and incubated for 16 hours at 37°C in 5% carbon dioxide (Table S2). The cells were then treated with 1 µM lapatinib or DMSO (vehicle) in duplicate. The cells were incubated for 4 hours, and then irradiated (IBL-637, cesium 137, dose rate of 1 Gy/min). The culture medium was changed 24 hours after treatment. After 6–20 days, cells were fixed and stained with crystal violet solution. Colonies containing >50 cells were counted. The surviving fraction was determined as the total number of colonies formed divided by the total number of cells plated multiplied by the plating efficiency, as determined in unirradiated cells in the presence of drug exposure.

Immunoblotting analysis
Western blotting was performed to detect pAKT, AKT, pEGFR, EGFR, pHER2, and HER2. Cells were treated 16 hours after plating in complete medium (containing FBS). Lapatinib (1 µM) or DMSO (vehicle) was added for 24 hours, and then proteins were extracted by sodium dodecyl sulfate lysis buffer (Tris–HCl 125 mM, 20% glycerol, and 4% SDS). Protein content was evaluated using a Bio-Rad® kit, and 10 µg of protein sample was loaded on a denaturing acrylamide NuPage Bis-Tris gel (Invitrogen). After migration, the proteins were transferred to nitrocellulose membrane. Antibodies used are listed in Table S3. Normalization was performed using an anti-β-actin antibody. Enhanced chemiluminescence (Amersham, Western Blotting Analysis System; GE Healthcare) was used for detection.

Statistical analysis
Statistical analyses were performed using GraphPad Prism Version 6. Paired t-test was used to evaluate differences in gene expression and Akt phosphorylation between lapatinib- and vehicle-treated cells. One-way analysis of variance was used to determine differences in Annexin V staining.

Results
Lapatinib reduces the expression of E6 and E7 oncogenes
SCC-47 and SCC-154 cells are depicted as HPV positive. While the effective transcription and levels of the E6 and E7 oncoproteins have been reported for SCC-47 cells,5 they have not been previously described for SCC-154 cells. Therefore, we performed quantitative RT-PCR, which showed similar levels of E6 and E7 in the two HPV-positive cell lines (data not shown). We evaluated if lapatinib treatment could affect the expression of the two transcripts. As shown in Figure 1, lapatinib significantly decreased E6 and E7 mRNA levels in both cell lines, with the exception of E6 in SCC-47, which was nevertheless close to statistical significance. As expected, E6 or E7 expression was not detected in SCC-9 and SCC-15, confirming the HPV-negative status of these cells (data not shown).

Lapatinib induces cell death of HPV-positive cells
We sought to determine whether lapatinib exerted an antiproliferative activity on the four HNSCC cell lines. Lapatinib efficiently reduced cell proliferation of the two HPV positive cell lines tested, with IC50 values of 0.36 µM (IC95 = 0.18 µM - 0.69 µM) and 0.02 µM (IC95 = 0.005 µM - 0.08 µM)
In an effort to clarify the molecular basis underlying the differential effects of lapatinib according to HPV status, we performed immunoblotting analysis to assess the expression level and the phosphorylation status of EGFR, HER2, and their downstream effector Akt. A 24-hour treatment with lapatinib, performed on cells plated in complete medium, induced a decrease in EGFR phosphorylation in SCC-47 and SCC-154 cells, even if in the latter cell line we could detect only a weak signal corresponding to the phosphorylated receptor (Figure 4A). In contrast, no modulation was observed in the HPV-negative cells (Figure 4B). Inhibition of HER2 phosphorylation was observed in all cell lines (Figure 4). In the HPV-positive cells, a significant decrease in Akt phosphorylation was observed upon lapatinib treatment (Figure 4A), of approximately 85% in both cell lines (see quantification in Figure 4A, right panels), in accord with the inhibition of receptor signaling. Oppositely, no modulation of Akt activation was observed in HPV-negative cell lines, indicating that Akt activation could be sustained by HER2-independent mechanisms in the SCC-9 and SCC-15 cells. Total protein levels were not significantly altered in all conditions tested.

The absence of Akt modulation after lapatinib treatment in HPV-negative cells is consistent with the lack of antiproliferative efficacy of lapatinib in these cells.
Lapatinib does not exert a radiosensitizing effect in HNSCC cells

We next investigated whether lapatinib could modulate the sensitivity of HNSCC cells to ionizing radiation by performing a clonogenic assay. Four hours before radiation exposure, cells were treated with 1 µM lapatinib to ensure sustained receptor inhibition in the lapatinib-sensitive cell lines. In the HPV-positive cell lines, lapatinib reduced the surviving fraction by 35% and 80% in SCC-47 and SCC-154, respectively (data not shown). No significant radiosensitizing effect was shown, although a limited trend toward decreased survival was detected in SCC-154 cells (Figure 5). As expected, we did not observe any significant effect of lapatinib treatment on the HPV-negative cells, consistent with the lack of efficacy of the drug on cell proliferation and on Akt activation.

Discussion

We tested the effects of lapatinib using multiple cellular models of HNSCC. This dual EGFR and HER2 inhibitor was tested in two HPV-positive and two HPV-negative cell lines, and was found to decrease AKT phosphorylation, a pivotal mediator of receptor tyrosine kinases signaling, in HPV-positive but not in HPV-negative cell lines. Accordingly, the induction of cell death by lapatinib was restricted to the HPV-positive cells. Of great interest, treatment with lapatinib reduced the levels of mRNAs coding for the two major HPV...
**Figure 4** Lapatinib treatment inhibits AKT signaling in HPV-positive cells.

Notes: Cells were treated with lapatinib (1 μM) or DMSO (vehicle control) 16 hours after plating. After 24-hour treatment, protein extraction was performed. The phosphorylation and levels of EGFR (Tyr1068), HER2 (Tyr1221/1222), and AKT (Ser473) were analyzed by Western blotting of HPV-positive (A) and HPV-negative cell lines (B). Beta-actin immunoblotting was used as a loading control. A representative picture of three independent experiments is shown. Quantification of AKT and pAKT was performed by densitometric analysis, and the mean ratio of pAKT/AKT from three independent experiments is depicted in the right panels. ***P < 0.001, paired t-test.

Abbreviations: HPV, human papillomavirus; DMSO, dimethylsulfoxide.

**Figure 5** Lapatinib treatment does not affect radiation sensitivity of HNSCC cells.

Notes: HPV-positive cells (A) and HPV-negative cells (B) treated with 1 μM lapatinib or DMSO (vehicle) were irradiated 4 hours later. Lapatinib was eliminated thanks to a medium removal 24 hours later. Colonies were stained with crystal violet solution. The surviving fraction was determined as the total number of colonies formed divided by the total number of cells plated multiplied by the plating efficiency, as determined in unirradiated cells in the presence of drug exposure.

Abbreviations: HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; DMSO, dimethylsulfoxide; Lapa, lapatinib.
oncogenes, E6 and E7. Even if this data needs to be confirmed by further observation (as restoration of p53 expression or pRb phosphorylation), reduction of papillomavirus oncogenes expression can contribute to the efficacy of lapatinib in HPV-positive cells. Consistent with the antiproliferative effect observed in the proliferation assay, clonogenic assay showed that lapatinib caused a reduction in clone size, which was limited to HPV-positive cells (data not shown). Nevertheless, we did not observe significant radiosensitization of these cell lines in clonogenic assays. This observation suggests that in these cellular models, survival to ionizing radiation could not be primarily due to AKT signaling. The results reported in the literature regarding the radiosensitizing effect of lapatinib are controversial. Zhou et al have reported radiosensitization in some cell lines but radioresistance in others upon treatment with lapatinib and ionizing radiation. In their work, one of the four cell lines tested was resistant to the antiproliferative and radiosensitizing effects of lapatinib, despite receptor inhibition. The proposed mechanism for resistance was the lack of Akt inhibition. By contrast Sambade et al reported that in breast cancer cells, radiosensitization by lapatinib is mediated primarily through inhibition of MEK/ERK pathway. Given that in all HNSCC cell lines tested we did not observe any radiosensitizing effect, it will be thus of interest to analyze if MEK/ERK activation is unchanged by lapatinib treatment in these cells and we will explore this possibility in our future works. Recently, similar discordant results have been observed in clinical studies of panitumumab, an anti-EGFR monoclonal antibody. Moreover, our results are in line with the effects of sorafenib, a broad-spectrum TKI. Pretreatment with sorafenib for 2–3 hours, at 24 hours and 48 hours, before radiation reduced the plating efficiency of HCT116 and SW480 cells but did not affect the relative surviving fraction. Interestingly, lapatinib did not significantly affect the proliferation of the two HPV-negative cell lines tested at concentrations of up to 10 μM. In a previous study, published in 2007 by Rusnak et al, the IC50 values for lapatinib in SCC-9 and SCC-15 were 0.331 μM and 0.267 μM, respectively. The difference between that study and our results may be a consequence of the different conditions used to perform the proliferation assays and different viability detection methods (methylene blue staining vs fluorescence-based REDOX indicator). Our results demonstrating negligible activity of lapatinib in SCC-9 and SCC-15 are consistent with those of clonogenic assays because no effects were observed, even on clone size (data not shown). Moreover, Western blot analysis demonstrated a decrease in HER2 phosphorylation (as expected, given the direct activity of lapatinib on the receptor), but this inactivation was not sufficient to inhibit activation of the PI3K/AKT pathway. Accordingly, we did not observe a radiosensitization effect of lapatinib.

Our study indicates a potential relation of HPV status and response to lapatinib. Nevertheless, it should be stressed that this observation, although indicative, is restricted to the limited cell lines tested. A generalization of the predictive value of HPV status for lapatinib efficacy will require screening of additional HNSCC cell lines and confirmation using gain-of-function and loss-of-function experiments, such as transfection of HPV oncogenes or RNAi against E6 and E7 transcripts. In preliminary experiments, we treated primary normal human and HPV18-immortalized keratinocytes with lapatinib, but lapatinib treatment was toxic to both cell lines and prevented us from carrying out clonogenic and immunoblotting analysis. Moreover, it should be noted that the effects of lapatinib in vivo may be significantly different as a consequence of influence of the tumor microenvironment and interplay with stromal cells. Further studies using animal models will be required to address this point.

The expression of HPV oncogenes in the HPV-infected cells could potentially affect the signaling pathway of EGFR and HER2, thus accounting for the differing sensitivity to lapatinib. A recent publication showed that E6 from HPV16 enhances the signaling of EGFR by activating mTORC1, and increases the internalization of activated receptors. Moreover, it has been demonstrated that HPV16 E5 inhibits the degradation of the EGFR in endosomal compartments, inducing prolonged retention of undegraded EGFR in intracellular vesicles. Finally, since EGFR signaling has been shown to be pivotal for the transforming activity of HPV16 E6/E7, it is conceivable to hypothesize that HPV-positive cells could be particularly responsive to EGFR inhibition.

EGFR family receptors are targets of interest in the clinical setting because they trigger pathways involved in the pathogenesis of human epithelial tumors. Thus, several molecules targeting these receptors have been developed and are currently being tested in squamous cell carcinomas. Heterogeneous results have been observed in cervical cancer and HNSCC (Table 1). Cetuximab, a monoclonal antibody targeting the extracellular binding domain of EGFR, has already demonstrated efficacy, in combination with RT, in an HNSCC phase III randomized study. However, the results of EGFR inhibitor use as monotherapy are not conclusive. For example, the first trials of TKIs in non-small-cell lung cancer comparing gefitinib or erlotinib vs placebo showed...
an improvement in tumor response rates with gefitinib and improved survival with erlotinib. Nevertheless, in studies comparing TKIs to standard chemotherapy, only one trial has shown an improved response in TKI-treated patients, while several other trials have failed to show superior efficacy of EGFR or HER2 inhibition. The phase II study from Harrington et al showed a superiority of lapatinib treatment in combination with chemoradiotherapy in p16-negative patients with locally advanced HNSCC, that nevertheless did not reach statistical significance. Moreover, due to the limited number of patients and the short follow-up period, in the same study it was not possible to evaluate the efficacy of lapatinib in p16-positive (surrogate marker of HPV infection) patients, and further studies are needed to address this point.

Our data suggest that lapatinib effectively inhibits the cell growth of two HPV-positive HNSCC cell lines and displays additive activity with ionizing radiation. Lapatinib was ineffective in HPV-negative HNSCC cells, suggesting that sensitizing effect of lapatinib is restricted to HPV-positive cells. Nevertheless, further studies are required to confirm HPV status as an indicator of the response to lapatinib and to identify the molecular mechanisms underlying the differential effects in HPV-positive vs uninfected cells.

Acknowledgment

This work was financially supported by Fondation Gustave Roussy, Institut National du Cancer (INCa), and GlaxoSmithKline.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol. 2009;6(5):266–277.
2. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol. 2005;16(Suppl 2):ii258–ii264.
3. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and unrelatated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612–619.
4. Kong CS, Narasimhan B, Cao H, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2009;74(2):553–561.
5. Kimple RJ, Smith MA, Blitzer GC, et al. Enhanced radiation sensitization in HPV-positive head and neck cancer. Cancer Res. 2013;73(15):4791–4800.
6. Rieckmann T, Tribius S, Grob TJ, et al. HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol. 2013;107(2):242–246.
7. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37:3–8.
8. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck. 2008;30(5):667–674.
9. Cavolato A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G. Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck. 2007;29(7):655–664.
10. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol. 2007;25(16):2164–2170.
11. Laimer K, Spizzo G, Gastl G, et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol. 2007;43(2):193–198.
12. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24(25):4170–4176.
13. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128–3137.
14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578.
15. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist. 2005;10(7):461–466.
16. Cohen MH, Williams GA, Sridhara R, et al. United States food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10(4):1212–1218.
17. Kondo N, Tsukuda M, Ishiguro Y, et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep. 2010;23(4):957–963.
18. Erjala K, Sundvall M, Junttila TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006;12(13):4103–4111.
19. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors potential therapy for cancer. Cancer Res. 2001;61(19):7196–7203.
20. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for advanced squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354(26):2733–2743.
21. Harrington KJ, El-Hariry IA, Holford CS, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(7):1100–1107.
22. Kimple RJ, Horton JK, Livasy CA, et al. Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. Oncologist. 2012;17(12):1496–1503.
23. Harrington K, Berrier A, Robinson M, et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer. 2013;49(7):1609–1618.
24. Prétet JL, Jacquard AC, Carcupino X, et al; EDITH Study Group. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. Int J Cancer. 2008;122(2):428–432.
25. Woodworth CD, Dieffendorf LP, Jette DF, et al. Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16. Virology. 2011;421(1):19–27.
26. Chinmayan P, Huang S, Valabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res. 2005;65(8):3328–3335.
41. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol 2011;22(3):712–717.

42. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5568–5577.

43. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5568–5577.

44. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646–8654.

45. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–1127.

46. Goncalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical carcinoma. Gynecol Oncol 2008;108(1):42–46.

47. Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemotherapy for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25(31):4880–4886.

48. Perez CA, Song H, Raez LE, et al. Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2012;48(9):887–892.

49. Gregoire V, Hamoir M, Chen C, et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol 2011;100(1):62–69.

50. Cohen EE, Haraf DJ, Kunnawakkam R, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010;28(20):3336–3343.

51. Rusthoven KE, Feigenberg SJ, Raben D, et al. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and radiotherapy in previously untreated head and neck squamous cell carcinoma: a Gynecologic Oncology Group Study. J Gynecol Cancer 2009;19(5):929–933.

52. Schilder RJ, Sill MW, Lee Y-C, Mannel R. A phase II trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res 2008;14(19):6324–6329.

53. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Phase II study of cisplatin plus cetuximab in head and neck cancer (SPECTRUM): an open-label phase 3 randomized trial. Lancet Oncol 2013;14(8):697–710.

54. Giralt J, Fortin A, Mesia R, et al. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 2012;30(suppl; abstr 5502). Available from: http://meetinglibrary.asco.org/content/93724-114. Accessed April 25, 2014.

55. Rustnak DW, Alligood KJ, Mullin RJ, et al. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 2007;40(4):580–594.

56. Scheme J, Munger K. The HPV16 E6 oncoprotein causes prolonged receptor protein tyrosine kinase signaling and enhances internalization of phosphorylated receptor species. PloS Pathog. 2013;9(3):e1003237.

57. Southgate SW, Herman B, McCance DJ. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J Virol. 1995;69(5):3185–3192.

58. Krause M, Gurtner C, Deuse Y, Baumann M. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. Int J Radiat Oncol Biol Phys. 2009;85(11):943–954.

59. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–1537.

60. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer: results of a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527–1537.

61. Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(3):495–500.

62. Farley J, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;121(2):303–308.

63. Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol. 2009;113(1):16–20.

64. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24(18):2866–2872.
Supplementary materials

Table S1 Quantitative RT-PCR primers and thermal protocol

| Primers sequences | Primers sequences | Primers sequences | Primers sequences | Primers sequences |
|-------------------|-------------------|-------------------|-------------------|-------------------|
| HPV16-E6 F: GAG CGA CCC AGA AAG TTA CCA | HPV16-E6 R: AAA TCC CGA AAA GCA AAG TCA | HPV16-E7 F: TCC AGC TGG ACA AGC AGA AC | HPV16-E7 R: CAC AAC CGA AGC GTA GAG TC |
| β-2 microglobulin F: TGCTGCTCCATGTTTGTATCT | β-2 microglobulin R: TCTCTGCTCCCCACCTCTAAGT |

Amplification program: 10 minutes at 95°C, then 40 cycles of 15 seconds at 95°C, and 60 seconds at 60°C

Table S2 Number of cells plated for clonogenic survival assays

| Irradiation dose (Gy) | SCC-9 (cells/well) | SCC-15 (cells/well) | SCC-47 (cells/well) | SCC-154 (cells/well) |
|-----------------------|-------------------|-------------------|-------------------|-------------------|
| 0                     | 250               | 1,000             | 500               | 1,000             |
| 1                     | 375               | 1,500             | 750               | 1,500             |
| 2                     | 500               | 2,000             | 1,000             | 2,000             |
| 4                     | 1,000             | 3,000             | 2,000             | 3,000             |

Table S3 List of antibodies

| Antibody | Reference | Catalog number | Amino acid phosphorylation site |
|----------|-----------|----------------|-------------------------------|
| Anti-AKT | Cell Signaling Technology | #4691 |             |
| pAKT     | Cell Signaling Technology | #4060 | Phospho-Akt (Ser473) |
| Anti-EGFR | BD Biosciences | #610017 |             |
| pEGFR    | Cell Signaling Technology | #2234 | Phospho-EGFR (Tyr1068) |
| Anti-HER2 | Cell Signaling Technology | #2242 |             |
| pHER2    | Cell Signaling Technology | #2249 | Phospho-HER2 (Tyr 1221/1222) |
| Anti-β-actin | AbCam | Ab49900 |             |